Introduction Product Name Lapatinib CAS No. 231277-92-2 Synonyms N-[3-Chloro-4-[(3-fluorophenyl)methoxy]phenyl]-6-[5-[(2-methylsulfonylethylamino)methyl]-2-furyl]quinazolin-4-amine; N-[3-Chloro-4-[(3-fluorophenyl)methoxy]phenyl]-6-[5-[[[2-(methylsulfonyl)ethyl]amino]methyl]-2-furanyl]-4-Quinazolinamine Molecular Formula C29H26ClFN4O4S Molecular Weight 581.06 MDL MFCD09264194 InChI 1/C29H26ClFN4O4S/c1-40(36,37)12-11-32-16-23-7-10-27(39-23)20-5-8-26-24(14-20)29(34-18-33-26)35-22-6-9-28(25(30)15-22)38-17-19-3-2-4-21(31)13-19/h2-10,13-15,18,32H,11-12,16-17H2,1H3,(H,33,34,35) Appearance White powder Property* Purity 98 % Melting Point 137-139 °C Boiling Point (760 mmHg) 750.7 °C Density 1.381 g/cm3 *The values provided are general information and not part of the product specification. Application Main Applications Lapatinib is an orally medicine for breast cancer and other solid tumours. Mainly used in the treatment of patients with advanced or metastatic breast cancer whose tumors overexpress HER2 (ErbB2). Packaging and Handling Grade Pharma Grade Packaging According to customer's request Storage and Transportation Storage in original sealed container. Recommended storage temperature: 4 °C. Protect from moisture, heat and foreign material.
Lapatinib is an orally medicine for breast cancer and other solid tumours.

CAS NO:231277-92-2

EC NO:

Molecular Formula:C₂₉H₂₆ClFN₄O₄S

Molecular Weight:581.0575

Synonyms:;4-Quinazolinamine, N-[3-chloro-4-[(3-fluorophenyl)methoxy]phenyl]-6-[5-[[[2-(methylsulfonyl)ethyl]amino]methyl]-2-furanyl]-;N-[3-Chloro-4-[(3-fluorophenyl)methoxy]phenyl]-6-[5-[(2-methylsulfonylethylamino)methyl]-2-furyl]quinazolin-4-amine;N-[3-chloro-4-[(3-fluorophenyl)methoxy]phenyl]-6-[5-[[[2-(methylsulfonyl)ethyl]amino]methyl]-2-furanyl]-4-Quinazolinamine;N-{3-chloro-4-[(3-fluorobenzyl)oxy]phenyl}-6-[5-({[2-(methylsulfonyl)ethyl]amino}methyl)furan-2-yl]quinazolin-4-amine;Lapatinib base;

Molecular Structure: